^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr del(17)(p13.1)

    Apply
    Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT02518555)
    Phase 2
    Jennifer Woyach
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    01/12/2016
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    TP53
    |
    Chr del(11q) • Chr del(17)(p13.1)
    |
    Imbruvica (ibrutinib)